S&P 500   4,001.53 (+1.64%)
DOW   32,460.80 (+1.34%)
QQQ   313.68 (+2.47%)
AAPL   161.17 (+2.12%)
MSFT   280.35 (+2.96%)
META   206.76 (+3.48%)
GOOGL   105.87 (+2.42%)
AMZN   100.71 (+2.04%)
TSLA   197.19 (+3.16%)
NVDA   273.99 (+3.52%)
NIO   9.33 (+2.64%)
BABA   87.87 (+5.04%)
AMD   102.39 (+4.93%)
T   18.52 (+0.71%)
F   11.74 (+2.26%)
MU   61.05 (+4.95%)
CGC   1.92 (+2.13%)
GE   92.65 (+3.42%)
DIS   96.64 (+1.83%)
AMC   4.57 (+5.30%)
PFE   40.42 (+1.02%)
PYPL   74.46 (+0.16%)
NFLX   320.25 (+8.97%)
S&P 500   4,001.53 (+1.64%)
DOW   32,460.80 (+1.34%)
QQQ   313.68 (+2.47%)
AAPL   161.17 (+2.12%)
MSFT   280.35 (+2.96%)
META   206.76 (+3.48%)
GOOGL   105.87 (+2.42%)
AMZN   100.71 (+2.04%)
TSLA   197.19 (+3.16%)
NVDA   273.99 (+3.52%)
NIO   9.33 (+2.64%)
BABA   87.87 (+5.04%)
AMD   102.39 (+4.93%)
T   18.52 (+0.71%)
F   11.74 (+2.26%)
MU   61.05 (+4.95%)
CGC   1.92 (+2.13%)
GE   92.65 (+3.42%)
DIS   96.64 (+1.83%)
AMC   4.57 (+5.30%)
PFE   40.42 (+1.02%)
PYPL   74.46 (+0.16%)
NFLX   320.25 (+8.97%)
S&P 500   4,001.53 (+1.64%)
DOW   32,460.80 (+1.34%)
QQQ   313.68 (+2.47%)
AAPL   161.17 (+2.12%)
MSFT   280.35 (+2.96%)
META   206.76 (+3.48%)
GOOGL   105.87 (+2.42%)
AMZN   100.71 (+2.04%)
TSLA   197.19 (+3.16%)
NVDA   273.99 (+3.52%)
NIO   9.33 (+2.64%)
BABA   87.87 (+5.04%)
AMD   102.39 (+4.93%)
T   18.52 (+0.71%)
F   11.74 (+2.26%)
MU   61.05 (+4.95%)
CGC   1.92 (+2.13%)
GE   92.65 (+3.42%)
DIS   96.64 (+1.83%)
AMC   4.57 (+5.30%)
PFE   40.42 (+1.02%)
PYPL   74.46 (+0.16%)
NFLX   320.25 (+8.97%)
S&P 500   4,001.53 (+1.64%)
DOW   32,460.80 (+1.34%)
QQQ   313.68 (+2.47%)
AAPL   161.17 (+2.12%)
MSFT   280.35 (+2.96%)
META   206.76 (+3.48%)
GOOGL   105.87 (+2.42%)
AMZN   100.71 (+2.04%)
TSLA   197.19 (+3.16%)
NVDA   273.99 (+3.52%)
NIO   9.33 (+2.64%)
BABA   87.87 (+5.04%)
AMD   102.39 (+4.93%)
T   18.52 (+0.71%)
F   11.74 (+2.26%)
MU   61.05 (+4.95%)
CGC   1.92 (+2.13%)
GE   92.65 (+3.42%)
DIS   96.64 (+1.83%)
AMC   4.57 (+5.30%)
PFE   40.42 (+1.02%)
PYPL   74.46 (+0.16%)
NFLX   320.25 (+8.97%)
NASDAQ:EVOK

Evoke Pharma - EVOK Stock Forecast, Price & News

$2.76
+0.13 (+4.94%)
(As of 03/23/2023 11:13 AM ET)
Add
Compare
Today's Range
$2.63
$2.88
50-Day Range
$2.63
$5.75
52-Week Range
$1.37
$16.80
Volume
11,598 shs
Average Volume
36,535 shs
Market Capitalization
$9.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

EVOK stock logo

About Evoke Pharma (NASDAQ:EVOK) Stock

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

EVOK Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Evoke Pharma Shares Up 4.8% on Higher 4Q Sales
Gastroenterology Market: The Growing Trend 2030
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)
Evoke Pharma
Earnings Preview: Evoke Pharma
See More Headlines
Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

EVOK Company Calendar

Last Earnings
3/21/2023
Today
3/22/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVOK
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-8,540,000.00
Net Margins
-391.75%
Pretax Margin
-390.45%

Debt

Sales & Book Value

Annual Sales
$1.62 million
Book Value
$1.31 per share

Miscellaneous

Free Float
3,000,000
Market Cap
$8.78 million
Optionable
Not Optionable
Beta
0.41

Key Executives

  • David A. Gonyer
    Chief Executive Officer & Director
  • Matthew J. D'Onofrio
    President, Chief Operating Officer & Secretary
  • Marilyn R. Carlson
    Chief Medical Officer













EVOK Stock - Frequently Asked Questions

How have EVOK shares performed in 2023?

Evoke Pharma's stock was trading at $2.68 on January 1st, 2023. Since then, EVOK stock has decreased by 1.9% and is now trading at $2.63.
View the best growth stocks for 2023 here
.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 26,100 shares, an increase of 54.4% from the February 13th total of 16,900 shares. Based on an average daily volume of 41,700 shares, the short-interest ratio is currently 0.6 days. Approximately 0.8% of the company's stock are sold short.
View Evoke Pharma's Short Interest
.

When is Evoke Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our EVOK earnings forecast
.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) posted its earnings results on Tuesday, March, 21st. The specialty pharmaceutical company reported ($0.53) earnings per share for the quarter. The specialty pharmaceutical company earned $0.80 million during the quarter. Evoke Pharma had a negative net margin of 391.75% and a negative trailing twelve-month return on equity of 178.36%.

When did Evoke Pharma's stock split?

Evoke Pharma's stock reverse split on the morning of Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David A Gonyer and Matthew J D'onofrio.
View institutional ownership trends
.

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $2.63.

How much money does Evoke Pharma make?

Evoke Pharma (NASDAQ:EVOK) has a market capitalization of $8.78 million and generates $1.62 million in revenue each year. The specialty pharmaceutical company earns $-8,540,000.00 in net income (profit) each year or ($2.7506) on an earnings per share basis.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The official website for the company is www.evokepharma.com. The specialty pharmaceutical company can be reached via phone at (858) 345-1494 or via email at tbui@theruthgroup.com.

This page (NASDAQ:EVOK) was last updated on 3/23/2023 by MarketBeat.com Staff